Literature DB >> 6817618

The effect of Ro 21-7634 on the antigen-induced production of bronchoconstrictive arachidonic acid metabolites in the guinea pig lung.

A F Welton, H J Crowley, G Folco, T Viganó.   

Abstract

Ro 21-7634 has previously been shown to inhibit histamine and SRS-A release from actively-sensitized guinea pig lung fragments upon antigen challenge. In the studies described herein, it was observed that Ro 21-7634 does not decrease SRS-A release but instead acts to inhibit the synthesis of this mediator. This was confirmed by studying SRS-A synthesis in vitro in rat peritoneal cells after challenge with ionophore A23187. In the peritoneal cell system, Ro 21-7634 exhibited an IC50 of 500 microM, in comparison with 5.8,11,14-eicosatetraynoic acid, phenidone and BW755C (IC50's of 2, 100, and 100 microM, respectively). When studied at 10(-4) and 10(-3) M in perfused guinea pig lung, Ro 21-7634 inhibited antigen-induced thromboxane A2 production by 68 and 96%, respectively. In this system, antigen is believed to induce thromboxane A2 production through the release of histamine and SRS-A from lung tissue. These mediators then interact at receptor sites in the lung parenchyma to induce thromboxane A2 synthesis. Ro 21-7634 could thus be inhibiting thromboxane A2 production by preventing the release of histamine and synthesis of SRS-A in the perfused lung system. Such a mechanism is suggested by the fact that although Ro 21-7634 was effective in inhibiting antigen-induced thromboxane production, it was ineffective in inhibiting thromboxane A2 production induced in the guinea pig lung system by the direct perfusion of histamine or SRS-A through the lung.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817618     DOI: 10.1007/bf01965923

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  22 in total

1.  Interaction between the release of SRS-A and of prostaglandins [proceedings].

Authors:  D M Engineer; P J Piper; P Sirois
Journal:  Br J Pharmacol       Date:  1976-07       Impact factor: 8.739

2.  The physicochemical characteristics and purification of slow-reacting substance of anaphylaxis.

Authors:  R P Orange; R C Murphy; M L Karnovsky; K F Austen
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

3.  Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs.

Authors:  P J Piper; J R Vane
Journal:  Nature       Date:  1969-07-05       Impact factor: 49.962

4.  Pharmacologic inhibition of the antigen-induced release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung tissues mediated by human IgE.

Authors:  T Ishizaka; K Ishizaka; R P Orange; K F Austen
Journal:  J Immunol       Date:  1971-05       Impact factor: 5.422

Review 5.  Slow reacting substance of anaphylaxis.

Authors:  R P Orange; K F Austen
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

6.  Structure of leukotriene C. Identification of the amino acid part.

Authors:  S Hammarström; R C Murphy; B Samuelsson; D A Clark; C Mioskowski; E J Corey
Journal:  Biochem Biophys Res Commun       Date:  1979-12-28       Impact factor: 3.575

7.  1-phenyl-3-pyrazolidone: an inhibitor of cyclo-oxygenase and lipoxygenase pathways in lung and platelets.

Authors:  G J Blackwell; R J Flower
Journal:  Prostaglandins       Date:  1978-09

8.  Modulation of the formation and release of bovine SRS-A in vitro by several anti-anaphylactic drugs.

Authors:  J F Burka; P Eyre
Journal:  Int Arch Allergy Appl Immunol       Date:  1975

9.  The pharmacology of isamoxole [2-methyl-n-butyl-n(4-methyloxazol-2-yl) propanamide] LRCL 3950, a new anti-allergic compound.

Authors:  W Dawson; W J Sweatman
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

10.  Ro 21-7634, a new antiallergic agent with potent oral activity.

Authors:  R A Salvador; L B Czyzewski; H Baruth; A Hooper; A Medford; D Miller; T van Trabert; B Yaremko; A F Welton
Journal:  Agents Actions       Date:  1981-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.